A Phase 1 interventional study of bilateral limb ischemic preconditioning (Doctormate, IPC-906X) in Bilateral Limb Ischemic Preconditioning and Intracranial Arterial Stenosis, sponsored by Ji Xunming. Completed at 1 site in China. Open to participants aged 80 Years to 95 Years. Per ClinicalTrials.gov, last updated 2012-07-27.
Sponsored by Ji Xunming · Phase 1, Interventional, and Prevention
Making a limb transiently ischemic induces ischemic tolerance in distant organs such as the heart. This study aims to evaluate the feasibility, safety and initial efficacy of using briefly repetitive bilateral limb ischemic preconditioning (BLIPC) to protect the brain in octogenarians with symptomatic intracranial arterial stenosis.
2,058 studies on the registry are indexed under Ischemia; 347 are open to participants now.
This study's enrollment of 58 is below the median of 80 across 1,359 interventional studies indexed under Ischemia.
Browse Ischemia studies →Ji Xunming is the lead sponsor of 3 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
5 minutes bilateral limb ischemic preconditioning treatment with an inflating tourniquets to 200 mmHg
Device: bilateral limb ischemic preconditioning (Doctormate, IPC-906X)
underwent equivalent medical treatments only
Device: bilateral limb ischemic preconditioning (Doctormate, IPC-906X, produced by Beijing Renqiao Institute of Neuroscience)five cycles of 5 minutes bilateral upper limb ischemia-reperfusion performed by inflating tourniquets to 200 mmHg, twice daily for 180 consecutive days, along with conventional medical treatment.
objective signs of tissue or neurovascular injury
objective signs of tissue or neurovascular injury felt to be due to cuff inflation, which was based on the judgment of the observers (blinded to study protocol) precluded continuation. Inspection included palpation of distal radial pulses, visual inspection (for local edema, redness, skin breakdown), and palpation for tenderness
Time frame: 180 days after treatment
levels of plasma biomarkers
levels of plasma myoglobin at baseline and at the 1st, 15th and 30th day during BLIPC treatment were monitored
Time frame: 180-day
This study is completed, as verified in Jul 2012. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Ji Xunming